Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±11.6%
EPS beat rate
88%
Acadia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders. With a market cap of $3 billion, its advancements in health care are particularly relevant as the industry seeks effective treatments for complex conditions.
Last quarter
In Q2 2026, Acadia reported an EPS of $0.18, significantly beating expectations of $0.06, which led to a 6.01% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+248.44%
Avg 1-day reaction
+1.70%
Investors are anticipating another strong performance from Acadia, especially after the substantial EPS beat last quarter. However, the lack of revenue guidance raises questions about sustainability.
Bull case
If Acadia continues to deliver strong EPS results, it could reinforce investor confidence and drive the stock higher, especially if they provide positive updates on revenue.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.
The print will turn on these.
Q1
What will the EPS be for Q3 2026?
Given the strong EPS surprise last quarter, investors will be keenly focused on whether Acadia can maintain this momentum.
Q2
Will there be any guidance on revenue growth?
Lack of revenue guidance in the previous quarter has left uncertainty, and any updates could significantly impact investor sentiment.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating Acadia's ability to sustain its EPS growth, especially given the recent strong performance and potential for new product developments.
Supporting evidence
Acadia has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.
The options market is pricing a significant move, suggesting that traders expect volatility that may not align with conservative consensus views.
Key risk
If EPS comes in below $0.10, it could challenge the current bullish sentiment.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it will determine if Acadia can sustain its recent performance and provide clarity on future growth.
Bull confirmed if
An EPS of $0.20 or higher would confirm the bull case, indicating continued strong performance.
Bear confirmed if
An EPS below $0.10 would confirm the bear case, suggesting potential challenges in growth.
What the market is pricing for the move.
Implied Move
±8.23%
Historical Avg
±2.7%
The options market is pricing in an 8.23% move, indicating that traders expect significant volatility around the earnings report.
Options are pricing ±11.6% while ACAD has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
47.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.2%, with a raw directional average of -0.6% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
99.68%
of float
Insider
0.33%
of float
Holders
474
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
42,912,904 sh · $843.2M
24.91%
0.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Acadia beats expectations, history suggests a potential stock increase of around 2.50%, confirming strong growth momentum.
In line / cautious
If results are in line with expectations but lack strong guidance, the stock may see a muted reaction, reflecting cautious investor sentiment.
Miss
A miss could lead to a decline of around 3.89%, as investors react negatively to disappointing results.
The lines on the call that would change the story.
Blackrock Inc.
22,515,173 sh · $442.4M
13.07%
4.5%
State Street Corporation
9,076,212 sh · $178.3M
5.27%
8.9%
Vanguard Portfolio Management LLC
8,838,450 sh · $173.7M
5.13%
1.9%
RTW Investments LP
7,144,524 sh · $140.4M
4.15%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.